

# CITATION REPORT

List of articles citing

## Beyond unfractionated heparin and warfarin: current and future advances

DOI: 10.1161/circulationaha.106.685974  
Circulation, 2007, 116, 552-60.

**Source:** <https://exaly.com/paper-pdf/41655696/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
188	Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. <b>2008</b> , 2, 461-462		
187	Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy. <b>2008</b> , 18, 4682-7		5
186	Mechanisms of thrombus formation. <b>2008</b> , 359, 938-49		1199
185	Triggers, targets and treatments for thrombosis. <b>2008</b> , 451, 914-8		736
184	Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation. <b>2008</b> , 32, 819-22		21
183	Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. <b>2008</b> , 28, 1354-73		78
182	The year in non-ST-segment elevation acute coronary syndrome. <b>2008</b> , 52, 1095-103		7
181	F?rmacos antitromb?ticos en el ?mbito extrahospitalario. <b>2008</b> , 10, 1493-1501		
180	The effect of anticoagulant pharmacotherapy on fracture healing. <b>2008</b> , 9, 1169-87		12
179	Will warfarin soon be pass? New approaches to stroke prevention in atrial fibrillation. <b>2008</b> , 52, 18-27		9
178	Commentary. Idraparinux versus standard therapy for venous thromboembolic disease. Extended prophylaxis of venous thromboembolism with idraparinux. <b>2008</b> , 20, 312-4		
177	Development of new anticoagulants: present and future. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2008</b> , 34, 779-93	5.3	26
176	Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2008</b> , 34, 39-57	5.3	40
175	The Artificial Lung. <b>2008</b> , 887-901		0
174	Indirect and direct anticoagulants predominantly inhibiting factor Xa. <b>2008</b> , 5, 177-192		5
173	Dabigatran etexilate: an oral direct thrombin inhibitor. <b>2008</b> , 5, 685-695		9
172	The search for new anticoagulants: dabigatran etexilate. <b>2008</b> , 5, 793-796		3

171	Low-Molecular-Weight-Heparins: A Review of Literature. <b>2008</b> , 5, 190-199		
170	Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 99, 651-2	7	1
169	Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. <b>2008</b> , 4, 1373-86		18
168	The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. <b>2009</b> , 5, 693-704		14
167	The direct factor Xa inhibitor rivaroxaban. <b>2009</b> , 190, 379-83		15
166	New anticoagulants - towards the development of an "ideal" anticoagulant. <b>2009</b> , 38, 13-29		21
165	Fondaparinux in acute coronary syndromes. <b>2009</b> , 5, 1615-23		3
164	Travel-related thromboembolism: mechanisms and avoidance. <b>2009</b> , 7, 1559-67		17
163	New anticoagulants in atrial fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2009</b> , 35, 574-85	5.3	18
162	Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure. <b>2009</b> , 16, 3028-40		6
161	Prophylactic Modalities: Pharmacologic and Mechanical Compression. <b>2009</b> , 20, 235-240		
160	Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 1897-905	15.4	20
159	Pulmonary thromboembolism. <b>2009</b> , 19, 30-52		69
158	In-hospital myocardial infarction following acute ischaemic stroke: an observational study. <b>2009</b> , 16, 1035-40		22
157	A new era for anticoagulants. <i>European Journal of Internal Medicine</i> , <b>2009</b> , 20, 562-8	3.9	39
156	New oral anticoagulants to revolutionise venous thromboembolism (VTE) management. <b>2009</b> , 13, 165-171		4
155	Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. <b>2009</b> , 7, 241-9		5
154	Thrombosis and Hemostasis. <b>2009</b> , 21-38		1

153	Anticoagulation monitoring. <b>2009</b> , 29, 283-304		6
152	Coagulation disorders in the ICU. <b>2009</b> , 30, 123-9, ix		10
151	Fondaparinux: a different weapon in the war on clot: update for the clinical nurse specialist. <b>2009</b> , 23, 125-7		
150	Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. <b>2009</b> , 250, 219-28		23
149	Blood coagulation: hemostasis and thrombin regulation. <b>2009</b> , 108, 1433-46		234
148	MYB and miR: a pair well matched. <b>2009</b> , 113, 499-500		
147	Bleeding hearts. <b>2009</b> , 113, 500-1		2
146	Hematology Pharmacology. <b>2009</b> , 20, 177-192		
145	Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice. <b>2009</b> , 20, 177-92		2
144	Update on fondaparinux: role in management of thromboembolic and acute coronary events. <b>2010</b> , 8, 96-103		5
143	Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. <b>2010</b> , 55, 609-16		28
142	Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 1263-71	7	288
141	Anticoagulation in percutaneous coronary intervention. <b>2010</b> , 2, 559-577		4
140	Secondary prevention strategies for coronary heart disease. <b>2010</b> , 29, 8-24		20
139	Tratamiento anticoagulante en el síndrome coronario agudo. Reflexiones sobre su estado actual. <b>2010</b> , 10, 3-11		
138	Recent therapeutic approaches to platelet activation in coronary artery disease. <b>2010</b> , 127, 108-20		17
137	Carotid stenting and bivalirudin with and without vascular closure: 3-year analysis of procedural outcomes. <i>Catheterization and Cardiovascular Interventions</i> , <b>2010</b> , 75, 420-6	2.7	12
136	Update on Rivaroxaban. <b>2010</b> , 3, CMBD.S5101		

135	New options with dabigatran etexilate in anticoagulant therapy. <b>2010</b> , 6, 339-49		20
134	Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care. <b>2010</b> , 42, 19-35		20
133	Study on unrecognized peripheral arterial disease (PAD) by ankle/brachial index and arterial comorbidity in Catania, Sicily, Italy. <b>2010</b> , 61, 524-9		27
132	Emerging anticoagulants for venous thromboembolism prevention. <b>2010</b> , 67, S17-25		5
131	Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. <b>2010</b> , 2, 479-492		0
130	Anticoagulants: newer ones, mechanisms, and perioperative updates. <b>2010</b> , 28, 667-79		7
129	Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. <b>2010</b> , 123, 536-41		44
128	Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry. <b>2010</b> , 26, 431-6		
127	Patient factors that influence warfarin dose response. <b>2010</b> , 23, 194-204		28
126	Old and new anticoagulant drugs: a minireview. <b>2011</b> , 43, 116-23		39
125	Anestesia in chirurgia ortopedica. <b>2011</b> , 16, 1-13		
124	New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better?. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 45-57	7	11
123	Factor Xa inhibitors for acute coronary syndromes. <b>2011</b> , CD007038		6
122	Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. <b>2011</b> , 334, 498-501		303
121	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. <b>2011</b> , 161, 261-268.e1-2		29
120	Insect natural products and processes: new treatments for human disease. <b>2011</b> , 41, 747-69		133
119	Anestesia en cirug�a ortop�dica. <b>2011</b> , 37, 1-14		
118	Future of anticoagulant therapy. <b>2011</b> , 29, 291-300		4

117	Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. <b>2011</b> , 15, R275		145
116	Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etxilate. <b>2011</b> , 3, CMT.S1176		
115	Novos anticoagulantes em cuidados intensivos. <b>2011</b> , 23, 68-77		3
114	Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 88-95	7	14
113	Pharmacologic Adjuncts to Endovascular Procedures. <b>2011</b> , 807-813		1
112	Drugs affecting coagulation and platelet function. 912-947		
111	Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban. <b>2011</b> , 18, 332-8		15
110	An update on the management and treatment of deep vein thrombosis. <b>2011</b> , 9, 207-17		2
109	Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer?. <b>2011</b> , 9, 350-7		3
108	Anesth�ie en chirurgie orthop�dique. <b>2011</b> , 8, 1-13		1
107	Inhibitors of propagation of coagulation: factors V and X. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 563-80	3.8	13
106	Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 2159-67	15.4	6
105	Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays. <b>2011</b> , 56, 992-7		1
104	Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty. <b>2011</b> , 131, 1739-43		5
103	Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. <b>2011</b> , 28, 460-72		14
102	The proof for new oral anticoagulants: clinical trial evidence. <b>2011</b> , 2, 7-14		1
101	From proof to practice: innovations in total hip and total knee replacement�modern anticoagulation. <b>2011</b> , 2, 3-5		
100	Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees. <b>2011</b> , 4, 1475-1487		3

99	Probing structural selectivity of synthetic heparin binding to Stabilin protein receptors. <b>2012</b> , 287, 20774-83		30
98	Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?. <b>2012</b> , 23, 680-7		17
97	Understanding the new emerging oral anticoagulants for venous thromboembolism prophylaxis. <b>2012</b> , 31, 265-78; quiz 279-80		4
96	Newer oral anticoagulant agents: a new era in medicine. <b>2012</b> , 8, 158-65		14
95	Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. <b>2012</b> , 44, 166-80		17
94	Novos anticoagulantes para a profilaxia do tromboembolismo venoso em cirurgia ortopédica de grande porte: revisão sistemática de ensaios clínicos randomizados. <i>Jornal Vascular Brasileiro</i> , <b>2012</b> , 11, 88-89	0.9	
93	Novel treatments for cardiovascular disease prevention. <b>2012</b> , 30, 257-63		11
92	Highly flexible and stable aptamer-caged nanoparticles for control of thrombin activity. <b>2012</b> , 2, 1577-1584		15
91	Old and new heparins. <i>Thrombosis Research</i> , <b>2012</b> , 129, 388-91	8.2	25
90	Analogues of N-(4-hydroxy-N-(4H,5H-naphtho[1,2-d]thiazol-2-yl)methanimidamide inhibit Mycobacterium tuberculosis methionine aminopeptidases. <b>2012</b> , 20, 4507-13		5
89	Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers. <b>2012</b> , 52, 499-510		5
88	New anticoagulants for treatment of venous thromboembolism. <i>European Journal of Internal Medicine</i> , <b>2012</b> , 23, 692-5	3.9	28
87	Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation. <i>PLoS ONE</i> , <b>2012</b> , 7, e29178	3.7	24
86	Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 766-87	3.5	15
85	Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk. <i>International Journal of Cardiology</i> , <b>2013</b> , 163, 5-18	3.2	15
84	Tratamiento de la trombosis venosa profunda iliofemoral y del síndrome postrombótico. <i>Angiología</i> , <b>2013</b> , 65, 218-227	0	1
83	Clasificación y tratamiento de la embolia pulmonar aguda. <i>Angiología</i> , <b>2013</b> , 65, 146-154	0	1
82	Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2013</b> , 27, 30-4	2.1	118

81	Cardiovascular Drugs. <b>2013</b> , 141-204		0
80	Perioperative Considerations for Surgical Emergencies. <b>2013</b> , 33-50		
79	Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR. <i>Circulation: Cardiovascular Interventions</i> , <b>2013</b> , 6, 131-8	6	17
78	Synthesis of ximelagatran, melagatran, hydroxymelagatran, and ethylmelagatran in H-3 labeled form. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2013</b> , 56, 334-7	1.9	12
77	Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. <i>Thrombosis</i> , <b>2013</b> , 2013, 183616		10
76	Identification and characterisation of novel inhibitors on extrinsic tenase complex from Bungarus fasciatus (banded krait) venom. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 700-15	7	5
75	Anticoagulant therapy in pregnant patients with metabolic syndrome: a review. <i>Current Pharmaceutical Biotechnology</i> , <b>2014</b> , 15, 47-63	2.6	6
74	Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245. <i>Expert Opinion on Therapeutic Patents</i> , <b>2014</b> , 24, 1139-48	6.8	1
73	Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2014</b> , 40, 121-8	5.3	15
72	Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. <i>Thrombosis Research</i> , <b>2014</b> , 134, 1198-204	8.2	93
71	Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. <i>Nature Chemical Biology</i> , <b>2014</b> , 10, 248-50	11.7	147
70	Chemoenzymatic synthesis of heparan sulfate and heparin. <i>Natural Product Reports</i> , <b>2014</b> , 31, 1676-85	15.1	142
69	Effect of aqueous extract and fractions of Fagonia arabica on in vitro anticoagulant activity. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2014</b> , 20, 844-50	3.3	4
68	Intentional overdose of warfarin in an adult: anticoagulant reversal in the ED. <i>American Journal of Emergency Medicine</i> , <b>2014</b> , 32, 1150.e1-2	2.9	10
67	Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention. A meta-analysis of randomised clinical trials. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 1010-20	7	14
66	Antivitamins B12--A Structure- and Reactivity-Based Concept. <i>Chemistry - A European Journal</i> , <b>2015</b> , 21, 11280-7	4.8	48
65	Anticoagulant and anti-inflammatory activity of a triterpene from Protorhus longifolia stem bark. <i>Journal of Medicinal Plants Research</i> , <b>2015</b> , 9, 613-619	0.6	1
64	Bioassay-guided fractionation of Melastoma malabathricum Linn. leaf solid phase extraction fraction and its anticoagulant activity. <i>Molecules</i> , <b>2015</b> , 20, 3697-715	4.8	6



63	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. <i>Advances in Hematology</i> , <b>2015</b> , 2015, 920361	1.5	8
62	Anticoagulation drug therapy: a review. <i>Western Journal of Emergency Medicine</i> , <b>2015</b> , 16, 11-7	3.3	121
61	New Triterpenes from the Fungus <i>Gloeophyllum odoratum</i> . <i>Chemistry of Natural Compounds</i> , <b>2015</b> , 51, 74-80	0.7	1
60	The design and synthesis of new synthetic low-molecular-weight heparins. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1135-45	15.4	17
59	Direct oral anticoagulants and venous thromboembolism. <i>European Respiratory Review</i> , <b>2016</b> , 25, 295-303	3.8	18
58	Heparin-Like Chitosan Hydrogels with Tunable Swelling Behavior, Prolonged Clotting Times, and Prevented Contact Activation and Complement Activation. <i>Biomacromolecules</i> , <b>2016</b> , 17, 4011-4020	6.9	31
57	New Therapeutic Agents in Thrombosis and Thrombolysis. <b>2016</b> ,		6
56	Venous Thromboembolism Prevention and Perioperative Management of Anticoagulants. <i>Hospital Medicine Clinics</i> , <b>2016</b> , 5, 242-267		
55	Anticoagulant and antithrombotic activities of low-molecular-weight propylene glycol alginate sodium sulfate (PSS). <i>European Journal of Medicinal Chemistry</i> , <b>2016</b> , 114, 33-40	6.8	45
54	[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine]. <i>Medizinische Klinik - Intensivmedizin Und Notfallmedizin</i> , <b>2017</b> , 112, 83-91	3.2	
53	Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 2356-2366	3.8	23
52	Gender differences in the effects of cardiovascular drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2017</b> , 3, 163-182	6.4	126
51	Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	60
50	The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. <i>Journal of Pharmacy and Pharmacology</i> , <b>2017</b> , 69, 1374-1380	4.8	1
49	The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2017</b> , 49, 237-244	2.4	6
48	Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta-analysis of studies. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 746-753	2.7	2
47	Enzyme-linked immunosorbent assays for therapeutic drug monitoring coumarin oral anticoagulants in plasma. <i>Analytica Chimica Acta</i> , <b>2018</b> , 1028, 59-65	6.6	7
46	New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 71-86	5.9	7

45	OBSOLETE: Pharmacology of Medications Used in the Treatment of Atherosclerotic Cardiovascular Disease. <b>2018</b> ,		
44	Pharmacology of Medications Used in the Treatment of Atherosclerotic Cardiovascular Disease. <b>2018</b> , 68-88		1
43	Acute Coronary Syndromes. <b>2018</b> , 2142-2151.e2		
42	Photolytic Properties of Antivitamins B. <i>Inorganic Chemistry</i> , <b>2018</b> , 57, 7838-7850	5.1	9
41	Advances in the preparation and synthesis of heparin and related products. <i>Drug Discovery Today</i> , <b>2020</b> , 25, 2095-2109	8.8	14
40	Chitosan hydrogels functionalized with either unfractionated heparin or bemiparin improve diabetic wound healing. <i>Biomedicine and Pharmacotherapy</i> , <b>2020</b> , 129, 110498	7.5	12
39	Low-molecular-weight fucosylated glycosaminoglycan and its oligosaccharides from sea cucumber as novel anticoagulants: A review. <i>Carbohydrate Polymers</i> , <b>2021</b> , 251, 117034	10.3	7
38	Cardiovascular Medications. <b>2021</b> , 597-642		1
37	Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin. <i>Critical Care Medicine</i> , <b>2021</b> , 49, 1129-1136	1.4	14
36	Periprocedural Anticoagulation and Antiplatelet Medications Management for Interventional Radiology Procedures. <i>Current Radiology Reports</i> , <b>2021</b> , 9, 1	0.5	
35	Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems. <i>Applied Nano</i> , <b>2021</b> , 2, 98-117	1	1
34	Acute Kidney Injury and Extracorporeal Membrane Oxygenation: Review on Multiple Organ Support Options. <i>International Journal of Nephrology and Renovascular Disease</i> , <b>2021</b> , 14, 321-329	2.5	2
33	Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	0
32	Functional and binding studies of gallic acid showing platelet aggregation inhibitory effect as a thrombin inhibitor. <i>Chinese Herbal Medicines</i> , <b>2021</b> ,	1.4	1
31	Acute Deep Venous Thrombosis. <b>2010</b> , 770-791		3
30	Novos anticoagulantes para a profilaxia do tromboembolismo venoso em cirurgias ortopédicas de grande porte. <i>Jornal Vascular Brasileiro</i> , <b>2011</b> , 10, 145-153	0.9	5
29	The evolution of anticoagulant therapy. <i>Blood Transfusion</i> , <b>2016</b> , 14, 175-84	3.6	30
28	Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. <i>Orthopedics</i> , <b>2011</b> , 34, 795-804	1.5	12

- 27 New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism. *Biomolecules and Therapeutics*, **2017**, 25, 461-470 4.2 10
- 26 Management of Pregnancy and Contraception in Congenital Heart Disease. **2009**, 194-220 4
- 25 Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. **2009**, 293-340
- 24 Antithrombotic therapy after acute myocardial infarction. *Cor Et Vasa*, **2009**, 51, 112-117 0.3
- 23 Fibrinolysis for Acute Myocardial Infarction. *Fundamental and Clinical Cardiology*, **2009**, 651-666
- 22 New Heparins: Synthetic Pentasaccharides. *Fundamental and Clinical Cardiology*, **2009**, 253-268
- 21 Antithrombotic Therapy for Atrial Fibrillation and Cardioversion. **2010**, 389-403
- 20 Evaluaci3n perioperatoria de la hemostasia. **2010**, 67-77
- 19 Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. **2011**, 971-991
- 18 Non-Invasive Coronary Angiography with Cardiac CT in Patients with Angina Pectoris. **2011**, 105-123
- 17 Developing Drugs from Sugars. **2012**, 259-296
- 16 Drugs for Thromboprophylaxis: Unfractionated Heparin, Low Molecular Weight Heparin, Warfarin, and Fondaparinux. **2013**, 53-65 2
- 15 Above the Knee Peripheral Artery Intervention. **2014**, 1-40 1
- 14 Coagulation, Anticoagulation, and Inflammatory Response. **2014**, 77-90 1
- 13 Interventional Treatment of the Above the Knee Peripheral Artery Disease. **2015**, 3161-3194
- 12 HEMBELERİN SUBKİTAN DE MOLEKİL AİRLİKLİ HEPARİN ENJEKSİYONU UYGULAMASINA İLİŞKİN BİLGİVE DAVRANIŞLARI. *Hacettepe Üniversitesi Hemirelik Fakültesi Dergisi*, 1-13 0
- 11 CHAPTER 9:Chemoenzymatic Synthesis of Heparan Sulfate and Heparin. *Chemical Biology*, **2019**, 207-225.4
- 10 Bioprospecting of Ethno-Medicinal Plants for Wound Healing. **2020**, 553-581

9	DİĞ MOLEKÜL AİRLİKLİ HEPARİN UYGULAMASI. <i>Journal of Anatolia Nursing and Health Sciences</i> , <b>2020</b> , 23, 169-175	0.1	
8	Venous thromboembolism in the elderly. A community-based perspective. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 100, 780-8	7	41
7	Evaluation of fibrinolytic medical therapy for patients with acute myocardial infarction. <i>ARYA Atherosclerosis</i> , <b>2012</b> , 8, 46-9	0.7	3
6	Antivitamins B.. <i>Vitamins and Hormones</i> , <b>2022</b> , 119, 221-240	2.5	0
5	Bivalirudin Versus Unfractionated Heparin in Patients with Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation.. <i>ASAIO Journal</i> , <b>2022</b> ,	3.6	0
4	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. <b>2013</b> , 332-397		1
3	Best Practices in Pharmacotherapy for Acute Coronary Syndromes. <i>US Cardiology Review</i> , 16,	0.4	
2	Current and future strategies to monitor and manage coagulation in ECMO patients. <b>2023</b> , 21,		0
1	Coumarin functionalized dimeric mesogens for promising anticoagulant activity: Tuning of liquid crystalline property. <b>2023</b> , 1283, 135336		0